Welcome to our dedicated page for Sinovac Biotech news (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech stock.
Sinovac Biotech Ltd. (NASDAQ: SVA) is a China-based global biopharmaceutical company focused on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The SVA news page on Stock Titan aggregates company press releases, regulatory updates, and third-party coverage so readers can follow developments affecting this vaccine manufacturer.
News about Sinovac frequently centers on its vaccine portfolio and public health role, including products such as CoronaVac® for COVID‑19, Healive® for hepatitis A, Inlive® for EV71-related Hand-Foot-Mouth disease (HFMD), and vaccines for varicella, influenza, poliomyelitis, and pneumococcal disease. Articles also highlight WHO prequalification of several Sinovac vaccines and the company’s history of developing vaccines during outbreaks of SARS, H5N1, H1N1, and COVID‑19.
Investors and observers can also use this page to track corporate governance, legal, and listing-related news. Recent company communications describe litigation in Antigua over PIPE shares and shareholder voting, competing claims regarding board composition, and court orders governing Sinovac’s board and corporate actions. Updates on proxy contests, special shareholder meetings, and dividend decisions are commonly reported through company press releases and furnished to the SEC on Form 6‑K.
Another key news theme is financial reporting and auditor engagement. Sinovac has issued announcements about the resignation and appointment of independent auditors, the engagement of UHY LLP and later Zhonghua Certified Public Accountants LLP, and its efforts to complete multi-year audits and file outstanding Form 20‑Fs and Form 6‑Ks. Related Nasdaq notices regarding late filings and a delisting determination letter are also disclosed in news items.
By reviewing the SVA news feed, readers can monitor Sinovac’s vaccine-related milestones, regulatory and legal developments, dividend actions, and progress toward meeting SEC and Nasdaq requirements. This page can be revisited regularly for the latest company-issued statements and market-relevant updates.
Sinovac Biotech Ltd. (NASDAQ: SVA) reported its unaudited financial results for the first half of 2022, showing a significant decline in sales to $1.2 billion from $11.0 billion the previous year. Net income attributable to common shareholders was $481.6 million ($4.84 per share), down from $5.1 billion ($51.42 per share) in the same period last year. Despite the decline, Sinovac's non-COVID vaccine sales grew by 37%. The company is heavily investing in R&D for various COVID-19 vaccines and has gained multiple WHO approvals for its products, expanding its global market reach.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced its live attenuated varicella vaccine received prequalification from the World Health Organization (WHO) on
Sinovac Biotech Ltd. (NASDAQ: SVA) announced its participation in CPHI Frankfurt from November 1-3, showcasing its extensive vaccine portfolio. The company will display its inactivated COVID-19 vaccine, CoronaVac®, among other products like the quadrivalent influenza vaccine and WHO prequalified vaccines. Chief Business Officer Helen Yang emphasized the significance of CPHI as a platform for business opportunities and new technologies. Sinovac aims to strengthen global partnerships and increase its market presence.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced approval from the Chilean Public Health Institute for a phase II clinical trial of its inactivated Omicron strain COVID-19 vaccine and a trivalent COVID-19 vaccine. The trial aims to assess the immunogenicity and safety of booster doses in 826 vaccinated adults. This study marks the world's first investigation of a multivalent inactivated COVID-19 vaccine. Sinovac continues to progress in vaccine development and plans further collaboration with global partners.
Sinovac Biotech Ltd. (NASDAQ: SVA) has received approval from the Hong Kong Health Bureau for its COVID-19 vaccine, CoronaVac, for children aged 6 months to 3 years. This vaccine will adhere to a three-dose schedule, with no restrictions for immunosuppressed children. The vaccine has previously been authorized for minors and adults aged over 3 years since February 15, 2022, and is approved in 14 countries across Latin America, Asia, and Africa. The phase III clinical studies indicate a good safety profile and immunogenicity for the target age group.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced the initiation of a phase III clinical trial for its inactivated quadrivalent influenza vaccine in Chile, collaborating with Pontificia Universidad Católica de Chile. The trial will recruit 1,600 volunteers to evaluate the vaccine's immunogenicity and safety. Participants aged 3 and above will receive either Sinovac's vaccine or a commercially available alternative. Observations will last 28 days post-inoculation. This trial aims to enhance the understanding of Sinovac's vaccine efficacy and safety.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its COVID-19 vaccine, CoronaVac, received emergency use approval for children aged 3 to 5 from Brazil's Health Regulatory Agency (Anvisa) on July 13. The same dosage for minors 6 to 17 and adults will be used, with no restrictions for immunosuppressed children. This decision followed extensive evaluations involving data from multiple sources, including the Butantan Institute and real-life evidence from Chile. As of July 14, 2022, CoronaVac is approved for emergency use in minors across 14 countries.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced that South Africa's Health Products Regulatory Authority granted conditional registration for its CoronaVac® vaccine for adults aged 18 and above, confirming its safety and efficacy. Previously given emergency use authorization on July 3, 2021, Sinovac has maintained compliance with safety monitoring and reporting obligations. The vaccine is now administered in two doses and has been supplied to over 60 countries, totaling nearly 2.9 billion doses.
SINOVAC Biotech Ltd. (NASDAQ: SVA) announced that its Poliomyelitis Vaccine (Vero Cell, Inactivated Sabin strains) received prequalification from the World Health Organization (WHO) on June 2, 2022. This approval enables the vaccine to be purchased by United Nations agencies as part of global polio eradication efforts. The vaccine is for children aged two months and older, following a three-dose immunization schedule. SINOVAC aims to collaborate with global health institutions to support the eradication of polio, particularly in areas with rising cases due to pandemic-related disruptions.
Sinovac Biotech Ltd. (NASDAQ: SVA) has been identified by the SEC under the Holding Foreign Companies Accountable Act (HFCAA) since May 4, 2022, following its 2021 annual report. This identification stems from issues related to its auditor's jurisdiction, which the company had anticipated. Sinovac, based in China, specializes in developing and manufacturing vaccines for various infectious diseases, including COVID-19. The company aims to monitor HFCAA developments while expanding its market presence both domestically and internationally.
FAQ
What is the market cap of Sinovac Biotech (SVA)?
